Nikesh Dattani1, Robert D Sayers1, Matthew J Bown1. 1. Department of Cardiovascular Sciences, NIHR Leicester Cardiovascular Biomedical Research Unit and British Heart Foundation Cardiovascular Research Centre, University of Leicester, Leicester, UK.
Abstract
INTRODUCTION: Diabetes mellitus appears to be negatively associated with abdominal aortic aneurysm; however, the mechanisms underlying this relationship remain poorly understood. The aim of this article is to provide a comprehensive review of the currently understood biological pathways underlying this relationship. METHODS: A review of the literature ('diabetes' OR 'hyperglycaemia' AND 'aneurysm') was performed and relevant studies grouped into biological pathways. RESULTS: This review identified a number of biological pathways through which diabetes mellitus may limit the presence, growth and rupture of abdominal aortic aneurysms. These include those influencing extracellular matrix volume, extracellular matrix glycation, the formation of advanced glycation end-products, inflammation, oxidative stress and intraluminal thrombus biology. In addition, there is an increasing evidence to suggest that the medications used to treat diabetes can also limit the development and progression of abdominal aortic aneurysms. CONCLUSION: The negative association between diabetes and abdominal aortic aneurysm is robust. Future studies should attempt to target the pathways identified in this review to develop novel therapeutic agents aimed at slowing or even halting aneurysm progression.
INTRODUCTION:Diabetes mellitus appears to be negatively associated with abdominal aortic aneurysm; however, the mechanisms underlying this relationship remain poorly understood. The aim of this article is to provide a comprehensive review of the currently understood biological pathways underlying this relationship. METHODS: A review of the literature ('diabetes' OR 'hyperglycaemia' AND 'aneurysm') was performed and relevant studies grouped into biological pathways. RESULTS: This review identified a number of biological pathways through which diabetes mellitus may limit the presence, growth and rupture of abdominal aortic aneurysms. These include those influencing extracellular matrix volume, extracellular matrix glycation, the formation of advanced glycation end-products, inflammation, oxidative stress and intraluminal thrombus biology. In addition, there is an increasing evidence to suggest that the medications used to treat diabetes can also limit the development and progression of abdominal aortic aneurysms. CONCLUSION: The negative association between diabetes and abdominal aortic aneurysm is robust. Future studies should attempt to target the pathways identified in this review to develop novel therapeutic agents aimed at slowing or even halting aneurysm progression.
Authors: Wenqiang Niu; Juan Shao; Benxiang Yu; Guolong Liu; Ran Wang; Hengyang Dong; Haijie Che; Lubin Li Journal: Front Cardiovasc Med Date: 2022-05-23
Authors: Xuejuan Ning; Ning Ding; Shoshana H Ballew; Caitlin W Hicks; Josef Coresh; Elizabeth Selvin; James Pankow; Weihong Tang; Kunihiro Matsushita Journal: Atherosclerosis Date: 2020-10-06 Impact factor: 5.162
Authors: Matthew J Nordness; B Timothy Baxter; Jon Matsumura; Michael Terrin; Kevin Zhang; Fei Ye; Nancy R Webb; Ronald L Dalman; John A Curci Journal: J Vasc Surg Date: 2021-10-23 Impact factor: 4.860